

Camilla Scott
Consultant Clinical Scientist
Head of the Department & Director of
Newborn Screening, Clinical Chemistry
Sheffield Children's Hospital
Western Bank, SHEFFIELD
S10 2TH

Email: camilla.scott@sch.nhs.uk

Executive Administrator

Sara Gardner Manchester Centre for Genomic Medicine 6th Floor, St Mary's Hospital, Oxford Road, Manchester M13 9WL, United Kingdom.

Tel: +44 161 276 6741 Fax: +44 161 850 1145 Email: sara.gardner@mft.nhs.uk

ORGANIC ACIDS QUALITATIVE ANALYSIS IN URINE BY GCMS

Index

a) Purpose of examination	2
b) Principle and method of the procedure	2
c) Analytical performance characteristics	2
d) Environmental and safety controls	3
e) Patient preparation	4
EQA	10
Examination processes	4
f) Interferences and cross reaction	4
g) Type of samples	4
General	2
h.) Type of container and additives	4
Hazards and Precautions	
i) Required equipment, reagent and consumables	4
Internal Quality Control	
j) Calibration procedures and metrological traceability	6
k) Procedural Steps	
I) principle of the procedure for calculating results including, where r	
the measurement of uncertainty of measured values	9
m) Instructions for determining quantitative results where a result is	
within the measurement interval	9
within the measurement interval	9 10
within the measurement interval	9 10 11
within the measurement interval n) Quality Control procedures o) Biological reference intervals or clinical decision values p) Reportable interval of examination results	9 10 11
within the measurement interval	9 11 11 10
within the measurement interval n) Quality Control procedures o) Biological reference intervals or clinical decision values p) Reportable interval of examination results Post -examination process Pre-Examination processes	9 11 11 10
within the measurement interval n) Quality Control procedures o) Biological reference intervals or clinical decision values p) Reportable interval of examination results Post -examination process Pre-Examination processes q) Alert/critical values, where appropriate	9 10 11 10 3
within the measurement interval n) Quality Control procedures o) Biological reference intervals or clinical decision values p) Reportable interval of examination results Post -examination process Pre-Examination processes q) Alert/critical values, where appropriate r) Laboratory clinical interpretation	9111011101111
within the measurement interval n) Quality Control procedures o) Biological reference intervals or clinical decision values p) Reportable interval of examination results Post -examination process Pre-Examination processes q) Alert/critical values, where appropriate r) Laboratory clinical interpretation Reagents	9 11 11 10 3 11
within the measurement interval n) Quality Control procedures o) Biological reference intervals or clinical decision values p) Reportable interval of examination results Post -examination process Pre-Examination processes q) Alert/critical values, where appropriate r) Laboratory clinical interpretation Reagents Repeat analysis on diagnostic sample	91011103111111
within the measurement interval n) Quality Control procedures o) Biological reference intervals or clinical decision values p) Reportable interval of examination results Post -examination process Pre-Examination processes q) Alert/critical values, where appropriate r) Laboratory clinical interpretation Reagents Repeat analysis on diagnostic sample Reruns and repeat extractions on the same sample	91110111011111114
within the measurement interval n) Quality Control procedures o) Biological reference intervals or clinical decision values p) Reportable interval of examination results Post -examination process Pre-Examination processes q) Alert/critical values, where appropriate r) Laboratory clinical interpretation Reagents Repeat analysis on diagnostic sample Reruns and repeat extractions on the same sample. s) Potential sources of variation	91011103115441
within the measurement interval n) Quality Control procedures o) Biological reference intervals or clinical decision values p) Reportable interval of examination results Post -examination process Pre-Examination processes q) Alert/critical values, where appropriate r) Laboratory clinical interpretation Reagents Repeat analysis on diagnostic sample Reruns and repeat extractions on the same sample s) Potential sources of variation t) References	911111011111111
within the measurement interval n) Quality Control procedures o) Biological reference intervals or clinical decision values p) Reportable interval of examination results Post -examination process Pre-Examination processes q) Alert/critical values, where appropriate r) Laboratory clinical interpretation Reagents Repeat analysis on diagnostic sample Reruns and repeat extractions on the same sample. s) Potential sources of variation	911111011111111



Camilla Scott
Consultant Clinical Scientist
Head of the Department & Director of
Newborn Screening, Clinical Chemistry
Sheffield Children's Hospital
Western Bank, SHEFFIELD

Email: camilla.scott@sch.nhs.uk

Executive Administrator Sara Gardner

Manchester Centre for Genomic Medicine 6th Floor, St Mary's Hospital, Oxford Road, Manchester M13 9WL, United Kingdom.

Tel: +44 161 276 6741 Fax: +44 161 850 1145 Email: <u>sara.gardner@mft.nhs.uk</u>

ORGANIC ACIDS

ORGANIC ACIDS QUALITATIVE ANALYSIS IN URINE BY GCMS

General

a) Purpose of examination

Acids, like all chemical compounds, are classified as either organic or inorganic. Organic acids occur in, or can be produced from, animal and vegetable matter. In addition to hydrogen, organic acids always contain carbon and at least one other element.

Organic acids occur as physiological intermediates in a variety of metabolic pathways. Organic acidurias are a group of disorders in which one or more of these pathways are blocked, resulting in a deficiency of normal products and an abnormal accumulation of intermediate metabolites (organic acids) in the body. These excess metabolites are excreted in the urine.

Organic acidurias typically present with either an acute life-threatening illness in early infancy or unexplained developmental delay with intercurrent episodes of metabolic decompensations in later childhood.

b) Principle and method of the procedure used for the examination

Organic acids are extracted from acidified, salt saturated urine. The extracts are evaporated to dryness under nitrogen and trimethylsilyl (TMS) derivatives formed using N_2 -O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) and pyridine. TMS derivatives are identified using gas chromatography mass spectrometry (GCMS) electron impact.

Derivatisation is necessary to produce compounds that are thermally stable, chemically inert and volatile below 300°C, so that separation can be achieved by GC. Compounds are partitioned between a moving inert carrier gas (He) and a stationary phase (non-volatile liquid) coated directly onto the inner surface of the capillary column, and elute at characteristic times (retention time). The eluent from the GC enters the electron ionisation chamber of the mass spectrometer where molecules are ionised and fragmented by collision with an electron beam, giving a unique fragmentation pattern (mass spectrum).

A compound is identified on the basis of its retention time and mass spectrum.

c) Analytical performance characteristics

This is a qualitative assay. Internal standards are used to determine the sensitivity; abundances of internal standards have to meet minimum criteria before an analysis is accepted.



Camilla Scott
Consultant Clinical Scientist
Head of the Department & Director of
Newborn Screening, Clinical Chemistry
Sheffield Children's Hospital
Western Bank, SHEFFIELD

S10 2TH

Email: camilla.scott@sch.nhs.uk

Executive Administrator

Sara Gardner

Manchester Centre for Genomic Medicine 6th Floor, St Mary's Hospital, Oxford Road, Manchester M13 9WL, United Kingdom.

Tel: +44 161 276 6741

Fax: +44 161 850 1145

Email: sara.gardner@mft.nhs.uk

Hazards and Precautions

d) Environmental and safety controls **COSHH**

Hazardous Substance

For all of the following wear purple nitrile gloves, handle only in a fume cupboard away from sources of ignition.

Concentrated hydrochloric acid: corrosive

Ethyl acetate: highly flammable.

Diethyl ether: extremely flammable, may form explosive

peroxides

Pyridine: highly flammable, harmful

BSTFA: Flammable, corrosive, toxic by inhalation and skin

contact.

Discarding TMS Extracts

The extracts are discarded into a yellow sharps bin in a fume cupboard after the sample has been reported. Please check in telepath if in doubt!

Samples must not be left by the side of the GCMS or discarded into waste for incineration bins in the open lab – the vials are not sealed after sampling and contain noxious harmful chemicals (BSTFA and Pyridine)

When necessary pool the extracts for the test mix, aliquot the test mix into glass vials and store in the cold room.

Fire Hazard.

Hazardous Substance

Ethyl Acetate Highly flammable

Store Winchester in flammable bin, store decanted bottle in fume cupboard

Diethyl Ether Extremely flammable

Store Winchester in flammable bin, store decanted bottle in fume cupboard, change decanted bottle every 6 months to reduce risk explosion due to build up of oxides

Pyridine highly flammable

Store bottle in fume cupboard, do not fill decanted bottle with more than 10ml liquid

BSTFA flammable

Store bottle in fume cupboard, after use blow in nitrogen to keep inert.

For full health and safety information relating to this examination procedure you must also read the latest MSDS for all associated reagents.

Pre-Examination processes



Camilla Scott
Consultant Clinical Scientist
Head of the Department & Director of
Newborn Screening, Clinical Chemistry
Sheffield Children's Hospital
Western Bank, SHEFFIELD

Email: camilla.scott@sch.nhs.uk

Executive Administrator

Sara Gardner Manchester Centre for Genomic Medicine 6th Floor, St Mary's Hospital, Oxford Road, Manchester M13 9WL, United Kingdom.

Tel: +44 161 276 6741

Fax: +44 161 850 1145

Email: sara.gardner@mft.nhs.uk

e) Patient preparation

None is required

In the event of a patient presenting with particular symptoms e.g. fits or hypoglycaemia it is important to obtain samples as near to the episode as possible.

f) Interferences and cross reaction

Samples collected using **Borate** as preservative are **not suitable**.

g) Type of samples

Random urine samples. Store at -20°C until analysed.

Extracts for GCMS (prepared by requesting lab).

Repeat samples may be required to reveal some abnormalities.

Post mortem CSF samples or Urine/bladder wash samples may be used if no other sample available.

Urgent samples

Urgent samples can either be run in isolation ASAP or analysed with the batch and run at the beginning of the batch.

Same day analysis is only guaranteed if the sample arrives in the lab by 1.30pm. Urgent analysis can sometimes be requested out of hours, analysis is arranged by the consultant clinical scientist covering the on call period.

Repeat analysis on diagnostic sample

If a sample from a batch is abnormal and indicative of a primary organic acidaemia then the sample is analysed in isolation ASAP to confirm the findings before the result is telephoned to the clinician.

Use the same chromatography number with an R on the end e.g. 6052R

Reruns and repeat extractions on the same sample

Use the same chromatography number as the original extraction with an R at the end e.g. 6052R

h.) Type of container and additives

20ml universal no preservative

Examination processes

i) Required equipment, reagent and consumables

PPE

Lab coat or plastic apron Purple nitrile gloves



Camilla Scott
Consultant Clinical Scientist
Head of the Department & Director of
Newborn Screening, Clinical Chemistry
Sheffield Children's Hospital
Western Bank, SHEFFIELD

Email: camilla.scott@sch.nhs.uk

Executive Administrator

Sara Gardner Manchester Centre for Genomic Medicine 6th Floor, St Mary's Hospital, Oxford Road, Manchester M13 9WL, United Kingdom.

Tel: +44 161 276 6741

Fax: +44 161 850 1145

Email: sara.gardner@mft.nhs.uk

Equipment

Benchtop GCMS: Shimadzu QP2010 Series GCMS system

Serial no C704643 70030

GC column: 'Agilent J and W GC COlumn'. Length 25m, diameter 0.2

mm. Part number 19091S-602

Centrifuge Jouan G4i
Heating/Drying Block Techne DB3
Sample concentrator Techne

Rotary Mixer Fume Cupboard

Consumables

Glass Pasteur pipettes Western laboratory Services-short form PP-150-S100

Plastic vials Burke Analytical 30111P-1232

Snap on Tops Agilent 5182-0550

7.5ml pyrex tubes Sigma Z28,111-5 screw tops Sigma Z14,508-4 Pipettes Gilson P100 ,.....

Reagents

5M Hydrochloric acid Fisher J/4270/17 Acid Bin 1

Bottle in use in OA skip

Sodium chloride Analar 27810.262 chemical cupboard A

Tub in use on bench- topped up from store

Anhydrous sodium sulphate (granular) Analar 1.06637 chemical cupboard A

Tub in use in fume cupboard- topped up

from store

Ethyl Acetate Rathburns RH1013 Solvent Bin 2

Bottle in use in fume cupboard

Diethyl ether Rathburns RG2013 Solvent Bin 2

Bottle in use in fume cupboard

BSTFA SuperIco fume cupboard

Pyridine Rathburns RH1046 fume cupboard

Decant into small bottle for in use

Heptadecanoic acid Sigma H-3500 green no 59

Methanol. Rathburns RH1019 Solvent Bin 2



Camilla Scott
Consultant Clinical Scientist
Head of the Department & Director of
Newborn Screening, Clinical Chemistry
Sheffield Children's Hospital
Western Bank, SHEFFIELD

Email: camilla.scott@sch.nhs.uk

Executive Administrator

Sara Gardner Manchester Centre for Genomic Medicine 6th Floor, St Mary's Hospital, Oxford Road, Manchester M13 9WL, United Kingdom.

Tel: +44 161 276 6741
Fax: +44 161 850 1145
Email: sara.gardner@mft.nhs.uk

Heptanoyl glycine MW = 187 available from Nigel Manning (green no 66)

5M HCI Dilute 570ml deionised water with 430ml 37% HCI

If need to make it up SG1.18 (fisher H/1200/PB17 Acid Bin 1)

Aliquot in use in OA skip

Internal Standards

Working standard A 75 mg heptadecanoic acid in 200 ml methanol.

Aliquot into 5ml glass tubes store in small freezer Aliquot in use at 4°C in metabolic fridge-stable one week – new aliquot at beginning of each week and write date removed from freezer on lid

of aliquot.

Stock Standard B 56 mg heptanoyl glycine in 100 ml water

Heptanoyl glycine 2.990 mmol/L. Store at -20°C in aliquots in small freezer

Working standard B Dilute 10 ml stock standard to 100 ml with

Heptanoyl glycine 0.299 mmol/L water.

Aliquot in 5 ml amounts.

Store at -20°C in metabolic storage freezer Aliquot in use at 4°C in metabolic fridge-stable one week – thaw aliquot at beginning of each week and write date thawed on lid of aliquot.

Please make a note in the relevant logs of any standards, QC or reagents made up and any lot changes

Solvent/Acid logs attached to relevant solvent bins
QC log in QC and calibration SOP folder

Standard logs attached to this SOP

Chemicals – write the date opened on the container

Update details on the entry in the reagent database on G drive

when a new reagent is received.

j) Calibration procedures and metrological traceability

Internal calibrations should be performed including changing the column and running the hydrocarbons for automatic annotation.

k) Procedural Steps

Sample Preparation



Camilla Scott
Consultant Clinical Scientist
Head of the Department & Director of
Newborn Screening, Clinical Chemistry
Sheffield Children's Hospital
Western Bank, SHEFFIELD

Email: camilla.scott@sch.nhs.uk

Executive Administrator

Sara Gardner Manchester Centre for Genomic Medicine 6th Floor, St Mary's Hospital, Oxford Road, Manchester M13 9WL, United Kingdom.

Tel: +44 161 276 6741

Fax: +44 161 850 1145

Email: sara.gardner@mft.nhs.uk

1. Make a worksheet, the telepath code is OA, ensure the patient details on the request forms and details on the worksheet match. The maximum number on a batch is 10, if more than 10 please check with the metabolic duty senior before proceeding, they will assess the requests and chose 10 based on the age of the patient and the clinical details.

- Defrost the samples in the water bath and mix thoroughly by inversion, ask AN Other to check samples against the worksheet.
- 3. Look up the creatinine result in telepath and write the result on the worksheet.
- 4. Look up the patient details for previous organic acid results, if there are any write the previous chromatography number on the worksheet (in the blank column), otherwise write N/A.
- 5. Transfer the pH and ketone (ACET2) stix test results to the worksheet. If these results are not available please see SOP 122004 for stix test methods.
- 6. Write the current chromatography number on the worksheet, refer to the previous GCMS worklist and the extracts on the GCMS carousel for the next available number.
- 7. Enter the results from the worksheet in to telepath. Reprint the worksheet.
- 8. Work out the amount of urine to be extracted and the amount of water to be added and write on the far right hand side of worksheet.

Urines are extracted to a creatinine of 2 mmol/L.

Calculation:-

Urine volume (ml) = 2 ÷creatinine (mmol/l)

Creatinine less than 0.8 mmol/l

If the urine volume required exceeds 2.5ml (i.e creat < 0.8) use two tubes or more for the extraction and label them with the number on the worksheet and "a,b", etc Only add internal standards to the tube numbered "a". Combine all the extracts for that sample into one tube at the drying down with nitrogen stage.

The drying down of the extract can be started before all the extraction steps are completed, after each extraction step add the extract in the tube with the sodium sulphate added, then decant the extract into the tube that is being dried down under nitrogen.

Creatinine greater than 8.0 mmol/l

Always extract 250µl urine



Email: camilla.scott@sch.nhs.uk

Camilla Scott Consultant Clinical Scientist Head of the Department & Director of Newborn Screening, Clinical Chemistry Sheffield Children's Hospital Western Bank, SHEFFIELD

Executive Administrator

Sara Gardner

Tel: +44 161 276 6741 Fax: +44 161 850 1145 Email: sara.gardner@mft.nhs.uk

Manchester Centre for Genomic Medicine

6th Floor, St Mary's Hospital, Oxford Road, Manchester M13 9WL, United Kingdom.

Insufficient urine to extract calculated amount

NB please check with senior BMS before using all the sample available as the urine may be needed for other tests.!!!!

Neatly cross out with one line the calculated amount and write the actual amount used. The method for the GCMS will alter according to the amount of urine extracted e.g. if only half the amount of calculated urine volume or less is used then the high sensitivity method is used on the GCMS, otherwise use the OA method

GCMS extract – extracted by other labs

Write patient details on the worksheet and allocate a chromatography number Add 20 µl pyridine to the extract and transfer into labelled GCMS plastic vial.

Extraction

Label tubes in triplicate (in black) numbered according to the worksheet. (3 rows of tubes)

- Using the EDP 2000, pipette the calculated volume of urine into the 1 appropriately labelled clean glass tube, and make up to 2 ml with distilled water. (discard any cracked or broken tubes).
- 2 Add 6 drops 5M HCL (check pH is less than 2 with pH paper).
- 3 Add 100 µl internal standard A and 100 µl internal standard B. NB if more than one tube used only add IS to tube "a"
- 4 Add solid sodium chloride to saturate. Mix on vortex mixer. Use an initial amount of approx. 1cm depth in the tube, add more if required during the extraction to ensure saturation.

Transfer the analysis to the fume cupboard. Wear purple nitrile gloves

- 5 Add 2 ml ethylacetate, cap the tubes with a well fitting top containing a plastic seal and mix for 2 minutes in a rack on rotary mixer in fume cupboard.
- 6 Centrifuge for 3 minutes at 1000 rpm using Juan G4i (ORG program)
- 7 Using a glass pasteur take off top organic layer into the second labelled tube.
- 8 Repeat steps 5-7
- 9 Repeat steps 5-7 but use 2 ml diethyl ether



Email: camilla.scott@sch.nhs.uk

Camilla Scott Consultant Clinical Scientist Head of the Department & Director of Newborn Screening, Clinical Chemistry Sheffield Children's Hospital Western Bank, SHEFFIELD

Executive Administrator

Sara Gardner Manchester Centre for Genomic Medicine 6th Floor, St Mary's Hospital, Oxford Road, Manchester M13 9WL, United Kingdom.

Tel: +44 161 276 6741 Fax: +44 161 850 1145 Email: sara.gardner@mft.nhs.uk

- 10 Dry combined extracts in the second tube by adding approx. 2g anhydrous sodium sulphate.
- 11 Decant dried extract into the third labelled tube and evaporate to dryness under nitrogen at 37°C in dry block heater, approx 20 minutes
- 12 To derivatise add 75µl of room temp. BSTFA and 20µl of pyridine to each dried extract, cap and vortex mix. (Refer to COSHH assessments for BSTFA and pyridine).
- 13 Place tubes in heating block at 80°C for 30 minutes (check temperature)
- 14 Transfer the cooled extracts into GCMS plastic vials labelled with the chromatography number allocated to that sample (see worksheet details). Cap tubes and place on the GCMS carousel – last 2 numbers of the chromatography number refer to the position on the carousel

Leave the glass extraction tubes in the fume cupboard overnight. Next morning the tubes can be placed in a bucket of water and sent for washing if there is no smell of solvent.

Writing the GCMS sample list

Sample information is entered into the batch table.

Method name is 'OA' and this injects a volume of 2 μl.

Place the request forms and worksheet on the desk next to the VDU screen for the GCMS.

The printed out worklist for the GCMS should be checked by another member of staff e.g. Clinical Scientist / qualified BMS, and the GCMS set to run. This person must wait until the first sample has been injected, the initialled worksheet and attached request forms can then be placed on the shelf next to the VDU.

GCMS Aquisition parameters

For details see GCMS Methods in GCMS SOP file in B1 Copies of the methods are backed up on the hard drive.

I) principle of the procedure for calculating results including, where relevant the measurement of uncertainty of measured values N/A This is a qualitative method

m) Instructions for determining quantitative results where a result is not within the measurement interval

N/A This is a qualitative method.



Camilla Scott
Consultant Clinical Scientist
Head of the Department & Director of
Newborn Screening, Clinical Chemistry
Sheffield Children's Hospital
Western Bank, SHEFFIELD

S10 2TH

Email: camilla.scott@sch.nhs.uk

Executive Administrator

Sara Gardner
Manchester Centre for Genomic Medicine
6th Floor, St Mary's Hospital, Oxford Road,
Manchester M13 9WL, United Kingdom.

Tel: +44 161 276 6741 Fax: +44 161 850 1145 Email: sara.gardner@mft.nhs.uk

Short form

n) Quality Control procedures

Internal Quality Control

Blank - monthly (extract 2mL water)

MCAD QC - monthly, extract 250µL urine. (Stored in metabolic assays freezer).

Refer to the document on internal QC and calibration material for further details. SOP 129005 and 129005_1

The abundance for the internal standards and the abnormal acylglycines for the IQC are recorded. See SOP 124204 for acceptance criteria for the MCAD and blank QC.

EQA

ERNDIM Qualitative Organic Acid Scheme – Heidelberg

This is a qualitative scheme where the abnormal metabolites have to be identified and a diagnosis made and clinical advice given. There are three sets of three samples per year. Reports for this scheme are located on the shelves in the metabolic "office" area.

Post -examination process

The Chromatogram and the "macros" are printed out when the batch has finished running (usually first thing the next morning so that any abnormalities or problems arising can be dealt with ASAP). The macros are a series of selective ion searches set up to be carried out automatically by the software.

The metabolites looked for are :

Heptanoylglycine.
Hept Gly
Hexanoylglycine
Suberylglycine
Sub Gly
Isovalerylglycine
Phenylpropionylglycine
PPG
Tigh deltaging

Tiglylglycine Tig Gly
3-methylcronylglycine 3 Me Crot Gly

IsobutyrylglycineIBG4-OH Butyrate4HBOrotic acidORTSuccinylacetoneSuccacSuccinylacetoacetateSuccacetoac

3-OH Glutarate 3OH Glut
Mevalonolactone Mev

3,6 epoxytetradecanedioate 3,6,epoxy

The chromatograms and their accompanying "macro" print out are then stapled together and placed with the request form. Write the age and clinical details on the



Camilla Scott
Consultant Clinical Scientist
Head of the Department & Director of
Newborn Screening, Clinical Chemistry
Sheffield Children's Hospital
Western Bank, SHEFFIELD

Email: camilla.scott@sch.nhs.uk

Executive Administrator Sara Gardner

Manchester Centre for Genomic Medicine 6th Floor, St Mary's Hospital, Oxford Road, Manchester M13 9WL, United Kingdom.

Tel: +44 161 276 6741 Fax: +44 161 850 1145 Email: <u>sara.gardner@mft.nhs.uk</u>

left hand side of the chromatogram just below the details for the laboratory number etc. Make a note of the relevant IS abundance and any acyl glycines detected on the "macros".

Give the chromatograms and request forms to a clinical scientist/metabolic senior BMS to check that there are no significant abnormalities or any that need repeating. The chromatograms can then be placed in the basket for annotation check in the GCMS room.

- o) Biological reference intervals or clinical decision values refer to SOP 124204
- p) Reportable interval of examination results
- q) Alert/critical values, where appropriate refer to SOP 124204
- r) Laboratory clinical interpretation

Reporting

Profiles are reported by a Clinical Scientist.

s) Potential sources of variation Changes in the column over time Aging of the liner Time of specimen collection. Deterioration of the sample.

t) References

Diagnosis of Organic Acidaemias by Gas Chromatography Mass Spectrometry Goodman and Markey, Alan R Liss, Inc., New York, 1981.

Organic Acids in Man: Analytical Chemistry, Biochemistry and Diagnosis of the Organic Acidurias
Chalmers and Lawson, Chapman and Hall, 1982.